What Researchers Did
Researchers conducted a multicenter study to assess the incidence and treatment of hemorrhagic cystitis in 1218 pediatric patients undergoing hematopoietic stem cell transplantation.
What They Found
Of 1218 pediatric patients, 44 (3.6%) developed hemorrhagic cystitis (HC) a median of 23 days post-transplant, with a higher incidence in allogeneic HSCT recipients (P=0.0001). Hyperbaric oxygen therapy significantly improved outcomes for grade II-III HC compared to prostaglandin therapy (P=0.02), and 37 patients (84%) recovered from HC. Age under 96 months and allogeneic HSCT were significantly associated with HC occurrence (P=0.008 and P=0.013, respectively), and 5-year survival was lower in patients who developed HC (43% vs 52%, P=0.03).
What This Means for Canadian Patients
Canadian children undergoing hematopoietic stem cell transplantation, especially younger patients or those receiving allogeneic transplants, may be at higher risk for hemorrhagic cystitis. Hyperbaric oxygen therapy could be a beneficial treatment option for these patients if they develop severe hemorrhagic cystitis.
Canadian Relevance
This study was conducted in Italy and has no direct Canadian connection.
Study Limitations
As a survey study, it may be limited by its observational design and potential for confounding factors in assessing treatment efficacy.